Article

Journey of a liquid biopsy

What is a liquid biopsy based test?

Certain lung cancer patients are not good candidates for tissue biopsy as this is an invasive procedure that carries risk. Liquid biopsy offers a non-invasive alternative for clinicians to identify clinically relevant biomarkers in patients to guide treatment decisions.

A liquid biopsy test looks for cancer cells or cell-free DNA (cfDNA) from a tumor that is circulating in the blood1. Obtaining blood samples is less invasive compared to traditional tissue biopsies.

journey of a liquid biopsy infographic
Opportunities for liquid biopsy

In non-small cell lung cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) testing is not performed in ~20% of eligible patients due to unavailable or insufficient tissue2.

Liquid biopsy can help provide results to clinicians and their patients within 1 day.

Liquid biopsy can help overcome complications of a lung biopsy and is playing an increasing role as a companion diagnostics in cancer management.

Disease Management

 

  • Detection of Resistance
  • Treatment Decisions
  • Treatment Monitoring
  • Diagnosis of Recurrence

 

Liquid biopsy offers a non-invasive approach for personalised patient care.

References

  1. https://www.cancer.gov/publications/dictionaries/cancer-terms, accessed March 2017
  2. 2015 European Lung Cancer Conference (ELCC): Abstract LBA2_PR. Presented April 17, 2015